# Novartis: Rhapsido shows sustained symptom improvement over 52 weeks in chronic inducible urticaria

- Published: 2026-11-13 11:30 UTC
- Section: Life & Health › Medicine
- Tags: Novartis Rhapsido, chronic inducible urticaria, CIndU treatment, 52-week data, chronic spontaneous urticaria, approval applications, urticaria safety profile
- URL: https://realtech.media/news/rt-ac9d183abc4424cfba07f860_novartis_rhapsido_shows/

**Novartis reports 52 weeks of sustained symptom improvement with Rhapsido in chronic inducible urticaria and plans to file additional approval applications.**

![Novartis: Rhapsido shows sustained symptom improvement over 52 weeks in chronic inducible urticaria](https://realtech.media/media/2026/11/50c6857459a9f6f8.jpg)
*U.S. Marine Corps photo by Sgt. Samuel Qin, Wikimedia Commons, Public domain*

Novartis said on Thursday evening that treatment with Rhapsido led to sustained symptom improvements over 52 weeks in patients with chronic inducible urticaria (CIndU), according to ad-hoc-news.de. [1] The company stated that the safety profile was comparable to that seen in earlier studies in chronic spontaneous urticaria (CSU). [1]

Rhapsido is already approved in many countries for the treatment of CSU. [1] On the basis of the new data, Novartis intends to submit additional marketing authorization applications for the treatment of CIndU. [1] The applications have not yet been submitted: the company only announced its intention to file them.

## Sources

1. [ad-hoc-news.de](https://www.ad-hoc-news.de/boerse/news/corporate-news/novartis-rhapsido-zeigt-anhaltende-wirkung-bei-chronischer-nesselsucht/70500601)

---

Source: RealTech, realtech.media — https://realtech.media/news/rt-ac9d183abc4424cfba07f860_novartis_rhapsido_shows/